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donors
Norbert Gleicher1,2*, Ann Kim1, David H Barad1,2, Aya Shohat-Tal1, Emanuela Lazzaroni1, Tamar Michaeli1,
Ho-Joon Lee1, Vitaly A Kushnir1 and Andrea Weghofer1,3Abstract
Background: Hypothesizing that redundant functional ovarian reserve (FOR) at young ages may clinically obfuscate
prematurely diminished FOR (PDFOR), we investigated in young oocyte donors genotypes and sub-genotypes of
the FMR1 gene, in prior studies associated with specific ovarian aging patterns, and determined whether they
already at such young age were associated with variations in ovarian reserve (OR). We also investigated racial as
well as FMR1 associations with menarcheal age in these donors.
Methods: In a cohort study we investigated 157 oocyte donor candidates and, based on the 95% CI of AMH,
divided them into normal age-specific (AMH greater or equal to 2.1 ng/mL; n = 121) and PDFOR (AMH < 2.1 ng/mL;
n = 36). We then assessed associations between numbers of trinucleotide repeat (CGGn) on the FMR1 gene and
FOR (based on anti-Müllerian hormone, AMH).
Results: FMR1 did not associate with AMH overall. Amongst 36 donors with PDFOR, 17 (42%) presented with at
least one low (CGGn < 26 ) allele. Remaining donors with normal FOR presented with significantly more CGGn
greater or equal to 26 (73.6% vs. 26.4%; P = 0.024) and higher AMH (P = 0.012). This finding was mostly the
consequence of interaction between FMR1 (CGGn < 26 vs. CGGn greater or equal to 26) and race (P = 0.013), with
Asians most responsible (P = 0.009). Menarcheal age was in donors with normal FOR neither associated with race
nor with FMR1 status. In donors with PDFOR race was statistically associated with CGGn (P = 0.018), an association
primarily based on significantly delayed age of menarche in African donors with CGGn < 26 in comparison to
African donors with CGGn greater or equal to 26 (P = 0.019), and Caucasian (P = 0.017) and Asian donors (P = 0.025)
with CGGn < 26.
Conclusions: CGGn on FMR1 already at young ages affects FOR, but is clinically apparent only in cases of PDFOR.
Screening for low FMR1 CGGn < 26 at young age, thus, appears predictive of later PDFOR.
Keywords: Fragile X gene, FMR1 gene, Ovarian reserve, Anti-müllerian hormone (AMH), Oocyte donorBackground
The FMR1 gene, located on the X chromosome, is widely
tested in prenatal medicine in attempts to prevent the
so-called fragile X syndrome, representing the one-
generational expansion of a premutation-range CGGn=55–200
to a full mutation, characterized by a CGGn>200. Based on
a newly defined normal range of CGGn=26–34, it has only* Correspondence: ngleicher@the chr.com
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2Foundation for Reproductive Medicine, 10021, New York, NY, USA
Full list of author information is available at the end of the article
© 2013 Gleicher et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orrecently in a number of publications been associated with
ovarian aging. Different mutations of the gene appear
associated with different rates of follicle depletion.
Lledo et al. recently, however, suggested that FMR1
screening should not be considered in pre-assessing po-
tential responses to ovarian stimulation [1], implying that
different FMR1 mutations do not correlate with variations
in functional ovarian reserve (FOR). We, in contrast, pre-
viously reported specific ovarian FMR1 genotypes and
sub-genotypes, defined by normal range of CGGn=26–34
(median, CGGn=30), associated with distinct ovarian agingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of all oocyte donors
Number of donor candidates 157
Caucasian (%) 109 (69.4)
Asian (%) 26 (16.6)
African (%) 22 (14.0)
Age at presentation (years) 24.6 ± 3.2
Age at menarche (years) 12.9 ± 1.5
BMI (kg/m2) 21.3 ± 2.4
AMH (ng/mL) 4.2 ± 2.6
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have since also proven associated with risk towards auto-
immunity [4] and, potentially, BRCA1/BRCA2-associated
cancer risks [5]. Moreover, Hoffman et al. recently reported
in a mouse analogue of human premutation range
(CGGn=55–200) primary ovarian insufficiency (POI) that
the model, in comparison to wild type mice, demon-
strated clear anatomic evidence of premature ovarian
aging (POA), including accelerated follicle loss [6].
Lledo and associates reached their conclusions, inves-
tigating oocyte yields in young oocyte donors [1]. Like
them, we previously also had been unable to demon-
strate differences in FOR in young oocyte donors [2].
We, therefore, to a degree based on their publication,
hypothesized that young oocyte donors, likely, do not
represent suitable subjects for such studies, as, at such
young ages, even impeded FOR may still create enough
redundancy to produce excellent oocyte yields [4].
Our earlier study involved, however, only 34 young
women [2]. We, therefore, decided to revisit the question
based on a larger patient sample, and a more sophisticated
study protocol. We here, therefore, investigated a much
larger egg donor population, stratified for normal FOR
and PDFOR.
Methods
This study investigated 157 consecutive oocyte donors,
selected for our center’s oocyte donor pool. We investi-
gated in this patient cohort whether their AMH levels at
time of initial presentation varied in association with dif-
ferent FMR1mutations, adjusted for race. We, in addition,
also investigated whether the donors’ menarcheal age was
affected by either race and/or FMR1 status.
Less than five percent of applicants are accepted into
our center’s oocyte donor pool. Donor selection involves
an initial screening step by questionnaire, followed by
two rounds of face-to-face interview and a final medical
testing round. Once candidates have passed this final
testing round, they become eligible for matching with re-
cipients. Once selected by a recipient, the donor under-
goes a second testing round in accordance with guidelines
issued by the United States Food and Drug Administra-
tion, the federal agency overseeing gamete donations in
the United States. Only if this testing round is satisfactory
is the donor considered “matched”.
In this study AMH and FMR1 testing was performed
on the day of the donor’s second face-to-face interview
at the center. All patients at our center undergo routine
FMR1 testing to screen for one-generational expansion
risk in offspring towards the fragile X syndrome. The test
is neither performed nor used to predict reproductive
performance of potential donors. Donor selection is,
therefore, not influenced by what genotypes or sub-
genotypes of FMR1 a given donor candidate represents.Our center’s Institutional Review Board (IRB), however,
based on prior published FMR1 studies from our center,
requires that donor candidates be informed if their FMR1
mutations are believed to potentially denote risk towards
PDFOR.
Ovarian FMR1 genotypes and sub-genotypes, as previ-
ously described, are based on a normal CGGn=26–34 range
[2,3]. This means that patients are considered to have nor-
mal (norm) genotypes if both alleles are in normal range.
They are considered to be heterozygous (het) if one allele
is outside, and homozygous (hom) if both alleles are
outside of normal range. Depending on whether abnor-
mal alleles are above or below normal range, het and hom
genotypes are further sub-divided into sub-genotypes. Het
genotypes are sub-divided into het-norm/high and het-
norm/low and hom genotypes into hom-high/high, hom-
high/low and hom-low/low. Every allele of CGGn<26 is,
therefore, considered a low allele. Norm and high alleles
in this manuscript are combined as CGGn≥26. FMR1
and AMH assays were performed by routine commer-
cial assays, as previously reported [2,3].
At time of acceptance into our center’s donor pool,
the mean age of donors was 24.5 ± 3.2 years, their body
mass index (BMI) was 21.3 ± 2.4 kg/m2 and their mean
AMH was 4.2 ± 2.6 ng/mL (Table 1).
The lower 95% CI for all AMH values, at <2.1 ng/mL,
was defined as diagnostic for PDFOR. Donors with AMH
above this range were, therefore, considered to have nor-
mal FOR.
Because distribution patterns of FMR1 genotypes and
sub-genotypes vary between races [7,8], all data were
adjusted for race. Racial assignments were made according
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donors assigned according to their racial self-definition.
Differences between continuous and categorical data
were calculated using Kruskal-Wallis, Mann–Whitney U,
two-way analysis of variance and Chi-Square tests, with
P < 0.05 considered statistically significant. All post hoc
procedures were performed using the Sidak test. Statistical
analyses were undertaken using the Statistical Package for
the Social Sciences 17.0 (SPSS, Chicago, IL, USA).
Oocyte donor candidates, like all other patients at our
center, at time of initial consultation sign an informed
consent, which allows for use of their medical record for
research purposes, as long as the patient’s identity is
protected and the medical record remains confidential.
Both conditions were met for this study, and the study,
therefore, qualified for expedited review by the center’s
IRB. Like infertility patients, oocyte donor candidates
also sign specific informed consents for genetic testing,
including FMR1 testing. Though, as already noted before,
FMR1 test results in our program are not utilized to select
oocyte donors, our IRB mandated that donors be in-
formed about the potential clinical significance if they
demonstrated other than norm genotypes.
Results
Table 1 summarizes the characteristics of all 157 oocyte
donor candidates. As the table demonstrates over two-
thirds were Caucasian; the remaining almost evenly split
between women of Asian and African descent.
The FMR1 genotype distribution was 83 norm (52.9%),
55 het (35.0%) and 19 hom (12.1%). Het were further
sub-divided into 16 het-norm/high (10.2%) and 39 het-
norm/low (24.8%), while hom was sub-divided into 9
hom-high/high (5.7%), 5 hom-high/low (3.2%) and 5 hom-
low/low (3.2%). A total of 49 (31.2%) donors, therefore,
demonstrated at least one low allele of CGGn<26, while
108 donors presented exclusively with CGGn≥26, representing
norm (CGGn=26–34) or high (CGGn>34) alleles.
Figures 1A, B present FOR data, based on AMH mea-
surements, with A representing donors with normal FOR
and B representing donors with PDFOR. Differences are
obvious, with normal FOR donors demonstrating uni-
formly mean AMH levels above 4 ng/mL, while donors
with PDFOR uniformly demonstrate mean AMH below
2 ng/mL.
When the 36 donors with PDFOR (AMH < 2.1 ng/mL)
were investigated separately, differences started coming
into focus: Among 36 donors with PDFOR, 17 (47.2%)
presented with at least one low FMR1 allele (CGGn<26)
and 19 (52.8%) with none. The remaining 121 donors with
normal FOR (AMH ≥ 2.1 ng/mL) were significantly more
likely to have a CGGn≥26 allele (73.6% vs. 26.4%; P = 0.024).
Normal FOR donors with a low (CGGn<26) allele still
demonstrated higher mean AMH levels than donors withCGGn≥26 (P = 0.012). As Figure 1A demonstrates, amongst
Caucasian and African donors AMH levels were similar
and did not differ significantly based on CGGn. Asian do-
nors, however, demonstrated, in comparison, significantly
higher AMH in association with presence of at least one
low (CGGn<26 ) allele (P = 0.009). They, therefore, are
likely primarily responsible for above described statis-
tical association with CGGn for the whole group of do-
nors with PDFOR.
These findings need to be contrasted to AMH levels in
donors with PDFOR, where, independent of race, all do-
nors presented with much lower AMH overall, but with
higher AMH levels in absence of a low allele (Figure 1B)
in each race, establishing an almost significant trend
(P = 0.057) in reversal to observation in donors with nor-
mal FOR. Figure 1B further demonstrates that Caucasians
and African donors once again demonstrated similar
AMH levels, while Asian donors, again, demonstrated
highest AMH levels, here, however, independent of CGGn.
When investigating menarcheal age, neither race nor
FMR1 status mattered in donors with normal FOR
(Figure 1C). Donors with PDFOR, however, demon-
strated significant differences by demonstrating significant
interaction between FMR1 CGGn and race (P = 0.018),
primarily based on significantly later menarche in African
women with low CGGn<26. African donors with low
CGG<26 demonstrated significantly later menarche than
African donors with CGGn≥26 (P = 0.019), and than
low FMR1 Caucasian (P = 0.017) and Asian (P = 0.025)
donors (Figure 1D).
Discussion
A so-called premutation-range genotype (CGGn=55–200)
of the FMR1 gene has for decades been associated with
highly increased risk towards primary ovarian insuffi-
ciency (POI), also called premature ovarian failure (POF)
[6,9]. Specific ovarian functions of the FMR1 gene have,
however, only in recent years been described in associ-
ation with newly described FMR1 mutations, which were
established based on a normal range of CGGn=26–34 [2,3].
We started to suspect a specific ovarian function of
FMR1 after noting a large distribution peak at CGGn=31–32
in a quite dated publication by Fu and associates [10],
suggesting a potentially new normal CGGn distribution
range for a new function of the gene. In assessing CGGn
in various populations, we then demonstrated that, inde-
pendent of racial background, a normal “ovarian” CGG
triple nucleotide range, indeed, appeared at CGGn=26–34,
close to, and including the distribution peak reported by
Fu et al. [2,11]. Defining such a normal range we then,
based on CGGn, can classify her as norm, het and hom [2].
Het and hom genotypes can be further sub-divided, based
on whether abnormal alleles have CGGn above (high) or
below (low) normal range [3].
Figure 1 AMH levels and menarcheal age in donors with normal and PDFOR. (A) AMH levels, based on CGGn on the FMR1 gene in donors
with normal FOR: AMH levels in the whole group differed significantly, based on FMR1 (P = 0.012), with the difference primarily being due to
Asian patients (see text). Independent of FMR1, the figure demonstrates similar AMH levels in Caucasian and African donors. Asian women with
low (CGGn<26) allele, however, demonstrate significantly higher AMH (P = 0.009) than Caucasians and Africans combined, and Asian women with
CGGn=≥26 (P = 0.006); (B) demonstrates AMH levels in donors with PDFOR: here, all three races demonstrate lower AMH with low FMR1 allele, the
difference almost reaching significance (P = 0.057); (C) demonstrates that with normal FOR age of menarche did not differ based on either race
or FMR1 status; (D) in contrast, demonstrates with PDFOR there was significant interaction between CGGn and race (P = 0.018), with African
donors reaching menarche at later age than Caucasians (P = 0.017) and Asians (P = 0.025), and amongst African donors those with CGGn<26
reaching menarche later than those with CGGn≥26 (P = 0.019).
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sociated with different ovarian aging patterns [2,3], different
pregnancy rates in association with in vitro fertilization
(IVF) [3] but also with risk towards autoimmunity [3,8]
and, likely, BRCA1/2 mutation-associated cancer risks [5],
suggesting, yet additional, previously unknown biological
functions for the FMR1 gene.The most interesting evolving mutation of FMR1, so
far, has been the het-norm/low sub-genotype, character-
ized by one allele in norm range and one at CGGn<26.
This low sub-genotype has been associated with a poly-
cystic ovary-like ovarian phenotype, which, because of
rapid recruitment, and therefore depletion of FOR, quickly
deteriorates into a phenotype characterized by premature
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lowest IVF pregnancy rates [3], autoimmunity [3,5] and,
likely, BRCA1/2-associated cancer risks [5]. Interestingly,
its “sibling” sub-genotype, het-norm/high, is associated
with highest FOR at very advanced female ages [12], and
is practically protective of autoimmune [3] and BRCA1/2-
associated cancer risks [5].
Here presented study for the first time offered the op-
portunity to examine the effects of the FMR1 gene on
the ovarian aging process in a very young, and appar-
ently normal cohort of females: young egg donors. For
the complete study cohort, CGGn of the FMR1 gene did
not affect OR. FMR1 effects, however, did become ap-
parent in donors who already at such young age (mean
24.6 years) suffered from PDFOR.
The study included 36 such donors, 17 (47.2%) with a
low allele and 19 (52.8%) without. Donors with PDFOR
were significantly less likely to present with CGGn≥26
than donors with normal FOR (P = 0.024). In young women
with absolutely normal FOR, redundancy of extra ovarian
reserve, therefore, indeed, appears substantial enough to
prevent FMR1-driven differences, caused by low FMR1
mutations, to become clinically apparent. We suspected
so much in a response to the recent publication by
Lledo et al. [1].
Higher AMH values, as observed in African and Asian
donors with normal FOR and low FMR1 CGGn<26 than
in donors with CGGn≥26 (P = 0.012, Figure 1A), may at
first glance surprise since higher AMH denotes better
FOR, resulting in better quantitative and qualitative IVF
outcomes [13]. Since these high AMH values appear
primarily the consequence of observations in Asian women
(Figure 1A), they, however, have to be viewed with caution
because young Asian women are not typically known to
present with high FOR (7,8). Moreover, though low FMR1
mutations of the het-norm/low sub-genotype have been
associated with the poorest IVF outcomes amongst all
FMR1 genotypes [3], this observation, too, has to be
understood within a proper context.
The het-norm/low sub-genotype of the FMR1 gene is
at young ages characterized by a PCOS-like ovarian
phenotype. PCOS, in turn, is associated with high FOR
and, therefore, high AMH levels. Young women with
low FMR1 mutations, while still during the PCOS-like
phase of their ovarian development, therefore, are expected
to demonstrate high AMH values. Considering small
numbers of Asian and African donors in this study, here
observed high AMH levels, especially amongst Asian do-
nors, have to be viewed with caution. Reported studies
actually suggest a preponderance of low FMR1 alleles in
African rather than Asian women [7,8].
This PCOS-like ovarian phenotype in low FMR1 muta-
tion carriers is, because of relatively rapid recruitment,
also characterized by early follicle depletion, by mid-agetransforming many of these women into patients with
PDFOR [3]. Young oocyte donors with low FMR1 alleles
and high FOR, therefore, may reflect ovarian phenotypes
pre-depletion.
This interpretation of here reported data is also sup-
ported by the previously noted distribution of FMR1
mutations amongst donors: Those who already had en-
tered PDFOR (n = 36), in almost half of cases (17/36;
47.2%) demonstrated low FMR1 alleles, while those with
normal FOR exhibited CGGn<26 in only 32/121 (26.5%;
P = 0.018).
Inversion of AMH data, as demonstrated in Figures 1A
(normal FOR; overall higher AMH with CGGn<26) and
1B (PDFOR; higher AMH with CGGn≥26), therefore,
may or may not be race-dependent. Data, however, do
appear to suggest that the FMR1 gene, indeed, does
affect FOR already at the young ages, though such effects
are in many young women not yet detectable by AMH
assessments at such early stages. Here presented data,
therefore, are in agreement with previously published
FMR1 data in older infertile patients, which suggest that
a low allele is prognostically predictive of PRFOR and
poorer pregnancy chances [3].
These data, however, in addition for the first time in
exclusively young, and apparently healthy females dem-
onstrate that a low FMR1 CGGn<26 allele appears pre-
dictive of PDFOR. While earlier cross-sectional studies
from our center in infertile patient populations were
suggestive of such an interpretation, here presented data
offer convincing evidence in a very young, and seemingly
fertile, highly selected egg donor population.
Screening for low FMR1 mutations in young women,
therefore, may offer the opportunity to detect genetically
predisposed women towards PDFOR already at very young
ages. Confirmation of risk by detection of a low FMR1 allele
then would allow for longitudinal FOR assessments with
AMH and FSH to either confirm or refute a diagnosis
of PDFOR.
This study also demonstrates that, even in the early
20s, some young women with low FMR1 mutations, and
therefore at risk for PDFOR, still have so much over-
abundant FOR that AMH measurements will not yet
allow for a diagnosis. Such women, therefore, will have
to be followed longitudinally with serial AMH and FSH
measurements. Confirmation of PDFOR at much younger
age than when currently PDFOR diagnoses are reached,
will allow affected women to plan their reproductive life
accordingly and/or consider fertility preservation through
social oocyte cryopreservation with much better success
and at lower cost than with later diagnosis.
The importance of low FMR1 mutations for the ovar-
ian aging process is further emphasized by here reported
menarcheal age data. While the total donor population
again does not reveal any race- or FMR1-based differences
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nificant differences based on race and FMR1 mutation
(Figure 1D). Here, significant interaction between CGGn
and race became apparent (P = 0.018), with African donors
entering menarche at older age than either Caucasians
or Asians.
That African donors behave so differently from Asian
and Caucasian donors has, once again, to be viewed with
caution and considered preliminary, in view of the rela-
tively small size of the African donor pool in this study.
Studying much older infertile women, we recently reported
that, adjusted for age and race, diminished functional
ovarian reserve (DFOR) in infertile women was statisti-
cally highly associated with younger age at menarche [13].
Since among all genotypes and sub-genotypes low FMR1
mutations appear most closely associated with DFOR, one
would expect to find younger menarcheal age amongst
donors with CGGn<26 than amongst donor with CGGn≥26.
That Asians demonstrate such a trend and Caucasians to
a lesser extent but that Africans demonstrate to a signifi-
cant degree exactly the opposite (Figure 1D) may suggest
racial differences as to how the FMR1 gene affects ovarian
aging. This study, however, does not allow for further
comments on the subject.
This study’s major weakness is the small size (n = 36)
of donors with PDFOR, as they ended up representing
the primary study population, demonstrating significant
positive associations. Considering the small size of this
cohort, the robustness of here reported statistical find-
ings is actually rather surprising. Our findings, however,
do require confirmation in larger young patient popula-
tions with PDFOR before here proposed conclusions can
be considered confirmed.
Maybe the most surprising finding of this study
was, however, the undisputed observation that 36/157
(22.9%) of carefully selected young oocyte donors, based
on 95% CI for AMH, were found with great likelihood
to suffer from PDFOR. This observation demonstrates
the limitations of currently used oocyte donor selection
methods. As noted under Materials and Methods, our
center, based on instructions from our center’s IRB, cur-
rently does not utilize FMR1 genotypes and sub-genotypes
in egg donor selection. Here presented data suggest that
FMR1-testing may, however, indeed, have a place in the
egg donor selection process.
Finally, this study, once again, points to the importance
of racial differences in reproductive medicine. We on
repeated occasions have made this point in recent publi-
cations [4,11], stressing the importance of racial adjust-
ments in studies of reproductive outcomes.
Conclusions
CGGn on FMR1 already at young ages affects FOR, but
is clinically apparent only in cases of PDFOR. Screeningfor low FMR1 CGGn<26 at young age, thus, appears
predictive of later PDFOR.
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